Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by 1900 Wealth Management LLC

1900 Wealth Management LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 26.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,566 shares of the biopharmaceutical company’s stock after selling 1,272 shares during the quarter. 1900 Wealth Management LLC’s holdings in Gilead Sciences were worth $289,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Nilsine Partners LLC grew its stake in shares of Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. raised its stake in shares of Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares in the last quarter. Financial Counselors Inc. raised its stake in shares of Gilead Sciences by 1.5% during the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in shares of Gilead Sciences by 3.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC increased its holdings in shares of Gilead Sciences by 10.3% during the 3rd quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 140 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $105.00 target price on shares of Gilead Sciences in a report on Friday. Barclays cut their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a research report on Monday, February 12th. Wells Fargo & Company cut their price objective on Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a research report on Monday, March 4th. UBS Group lowered their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Finally, Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $84.71.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Up 0.4 %

GILD stock traded up $0.28 during mid-day trading on Tuesday, reaching $67.23. 1,468,088 shares of the company traded hands, compared to its average volume of 7,253,361. The stock has a market cap of $83.71 billion, a price-to-earnings ratio of 14.88, a P/E/G ratio of 0.92 and a beta of 0.19. The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. Gilead Sciences, Inc. has a fifty-two week low of $65.90 and a fifty-two week high of $87.86. The firm’s 50 day moving average price is $71.81 and its 200 day moving average price is $76.51.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. The company had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. During the same quarter last year, the firm posted $1.67 EPS. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. As a group, equities research analysts predict that Gilead Sciences, Inc. will post 6.55 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.58%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. Gilead Sciences’s dividend payout ratio is currently 68.44%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.